APA 6th Edition Tudorić, N. (2018). Azitromicin i kronične plućne bolesti. Medicus, 27 (2 Sumamed), 165-170. Preuzeto s https://hrcak.srce.hr/214610
MLA 8th Edition Tudorić, Neven. "Azitromicin i kronične plućne bolesti." Medicus, vol. 27, br. 2 Sumamed, 2018, str. 165-170. https://hrcak.srce.hr/214610. Citirano 29.01.2020.
Chicago 17th Edition Tudorić, Neven. "Azitromicin i kronične plućne bolesti." Medicus 27, br. 2 Sumamed (2018): 165-170. https://hrcak.srce.hr/214610
Harvard Tudorić, N. (2018). 'Azitromicin i kronične plućne bolesti', Medicus, 27(2 Sumamed), str. 165-170. Preuzeto s: https://hrcak.srce.hr/214610 (Datum pristupa: 29.01.2020.)
Vancouver Tudorić N. Azitromicin i kronične plućne bolesti. Medicus [Internet]. 2018 [pristupljeno 29.01.2020.];27(2 Sumamed):165-170. Dostupno na: https://hrcak.srce.hr/214610
IEEE N. Tudorić, "Azitromicin i kronične plućne bolesti", Medicus, vol.27, br. 2 Sumamed, str. 165-170, 2018. [Online]. Dostupno na: https://hrcak.srce.hr/214610. [Citirano: 29.01.2020.]
Sažetak Soon after it was introduced in everyday clinical practice, azithromycin became widely used for the treatment of a number of bacterial infections, especially those affecting the respiratory tract. Over time, a growing body of research found that macrolides exert significant immunomodulatory effects, thus significantly expanding indications for azithromycin, a macrolide antibiotic with numerous advantages over the other antibiotics from its class. As opposed to short-term use of azithromycin as an antimicrobial agent, its immunomodulatory effect is presented only after long-term use over a course of several months. This paper briefly addresses the use of azithromycin in patients with chronic respiratory diseases where the effects of the drug are based on its immunomodulatory effects.